RE: Humanised mouse and Eli mentioned in quick succession???8 Oct 2020 00:33
Vlad on 24th June 2019:
Vladislav Sandler, Chief Executive Officer, commented, "We are excited by the potential of the ApbHC, a new generation of our humanized mice. The ApbHC has allowed us to rapidly obtain in vivo data on the efficacy of our CDX antibodies against AML. We are actively developing and expanding the potential use of the ApbHC for disease modeling, the development of new therapeutics, and biodefense applications. Our ApbHC has also generated significant interest from third parties who also see its potential for disease modeling and drug development."
Hemo press release in April:
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for deadly blood diseases, is deploying its groundbreaking research and technologies to develop potential treatments for COVID-19.
Using its humanized mice, the Advanced peripheral blood Hematopoietic Chimera (“ApbHC”), which were developed to model blood and autoimmune diseases and to test treatments, Hemogenyx will seek to discover human neutralizing antibodies – antibodies that are typically developed by the human immune system to neutralize invading viral pathogens – that could be used to fight SARS-CoV-2 (the virus that causes COVID-19) infections.
Prior to the appearance of COVID-19, Hemogenyx had been working independently and with a number of pharmaceutical company partners to utilize the exceptional features of ApbHC to identify and isolate human neutralizing antibodies for use as antiviral therapies. The Company’s methodology is generally applicable to new pathogens including viruses, as previously described in the Company’s original announcement of the development of ApbHC.
With the outbreak of COVID-19, the Company concluded that it would potentially be applicable to the SARS-CoV-2 virus. As part of its studies, Hemogenyx will transplant cells from blood samples from patients who are either recovering or have already recovered from COVID-19 into its ApbHC humanized mice. The process will allow the Company’s scientists to recreate a set of anti-SARS-CoV-2 virus antibodies which could be used for the treatment of COVID-19.
Sign In
Follow the stocks
